Evommune, Inc.
EVMN- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0002044725
In the last 90 days, Evommune, Inc. insiders filed 2 open-market purchases and 0 sales; 105 institutions reported holding it in 13F filings for Q2 2026, worth $462.5M in total; no superinvestor holds it.
Holders of 5% or more of EVMN
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Evommune, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| LSP 7 Cooperative UA | 13D/A | 14.70%5.29M shares | −1.00 ppfrom 15.70% | Nov 14, 20252 filings | Feb 19, 2026 | SEC |
| Pivotal bioVenture Partners Fund I, L.P. | 13G | 10.90%3.44M shares | New | Feb 13, 20261 filing | Feb 13, 2026 | SEC |
| Ra Capital Management, L.P. | 13D/A | 9.70%3.49M shares | −1.30 ppfrom 11.00% | Nov 17, 20252 filings | Feb 17, 2026 | SEC |
| Price T Rowe Associates Inc | 13G | 5.40%1.94M shares | New | Aug 14, 20261 filing | Aug 14, 2026 | SEC |
| Point72 Asset Management, L.P. | 13G | 5.30%1.91M shares | New | Jul 16, 20261 filing | Jul 16, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
9 Schedule 13D and 13G filings on Evommune, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Aug 14, 20264:17 PM ET | Andera Partnersand 3 others | 13G/A | 3.90%1.39M shares | −2.10 ppfrom 6.00%Below 5% | Jun 30, 2026 | SEC |
| Aug 14, 202610:38 AM ET | Price T Rowe Associates Inc | 13G | 5.40%1.94M shares | New | Jun 30, 2026 | SEC |
| Jul 16, 20265:03 PM ET | Point72 Asset Management, L.P.and 2 others | 13G | 5.30%1.91M shares | New | Jul 15, 2026 | SEC |
| Feb 19, 20264:30 PM ET | LSP 7 Cooperative UAand 1 other | 13D/A | 14.70%5.29M shares | −1.00 ppfrom 15.70% | Feb 12, 2026 | SEC |
| Feb 17, 20267:28 PM ET | Ra Capital Management, L.P.and 3 others | 13D/A | 9.70%3.49M shares | −1.30 ppfrom 11.00% | Feb 12, 2026 | SEC |
| Feb 13, 20264:10 PM ET | Pivotal bioVenture Partners Fund I, L.P.and 12 others | 13G | 10.90%3.44M shares | New | Dec 31, 2025 | SEC |
| Nov 17, 20254:44 PM ET | Ra Capital Management, L.P.and 3 others | 13D | 11.00%3.46M shares | New | Nov 7, 2025 | SEC |
| Nov 17, 20254:33 PM ET | Andera Partnersand 3 others | 13G | 6.00%1.90M shares | New | Nov 7, 2025 | SEC |
| Nov 14, 20254:30 PM ET | LSP 7 Cooperative UAand 1 other | 13D | 15.70%4.93M shares | New | Nov 7, 2025 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Evommune, Inc. shares.
No Form 144 notices for Evommune, Inc. are on file.